GENERAL INFORMATION

Meeting: 5th Euro VT/VF Meeting 2013

Date: 6./7. December 2013

Scientific Committee:

K.-H. Kuck, Hamburg (DE), P. Della Bella, Milan (IT) G. Hindricks, Leipzig (DE), P. Jais, Bordeaux (FR)

Venue:

Grand Hyatt Berlin

Marlene-Dietrich-Platz 2, D-10785 Berlin

Tel.: +49 (0) 30 25 53 12 34, Fax: +49 (0) 30 25 53 12 35

E-Mail: berlin.grand@hyatt.com, www.berlin.grand.hyatt.com

Language: The official conference language is English.

Registration fee:

By 15. Oct., 2013: € 485,-, From 16. Oct., 2013: € 600,-

Registration fee includes:

- Admission to the Scientific sessions
- Congress Material
- Coffee breaks & Lunch
- Certificate of attendance

Online registration: www.euro-vtvf.eu

Organizer:

Prof. Dr. Karl-Heinz Kuck
Euro EP uG
c/o Asklepios Klinik St. Georg
Lohmühlenstraße 5, D-20099 Hamburg
Tel.: +49 (0) 40 18 18-85 23 08, Fax: +49 (0) 40 18 18-85 44 44

E-Mail: k.kuck@asklepios.com, www.asklepios.com

Congress Agency:

wkonect

wikonect GmbH

Hagenauer Straße 53, D-65203 Wiesbaden

Tel.: +49 (0) 611 204809-0, Fax: +49 (0) 611 204809-10

E-Mail: info@wikonect.de, www.wikonect.de





The meeting is accredited by:
The European Board of Accreditation in Cardiology







Partner:











PREFACE

Dear colleagues, Dear friends,

Encouraged by the great success of the last four meetings, we will be convening the 5th Euro VT/VF Meeting on 6./7. December 2013 in Berlin. We would like to cordially invite you to attend our meeting.

The first treatment of ventricular tachycardia by open heart surgery in the early 1980's and by percutaneous catheter procedures, using first DC Shock and later radiofrequency, current in the mid 1980's is almost more than 30 years ago. The experience was limited to patients with life-threatening ventricular tachycardia refractory to medical treatment. These procedures were performed in a few centers around the world by only very experienced physicians.

The introduction of the implantable defibrillator by Michel Mirowski substantially changed the treatment of VT/VF and made catheter ablation a procedure, which in many countries was mostly performed in patients following multiple ICD interventions. In most patients without structural heart disease new mechanistic insights based on catheter ablation procedures made catheter ablation a first line treatment.

Following the enthusiasm in catheter ablation of atrial fibrillation new interests of physicians and industry has initiated an upcoming revival of ventricular tachycardia / fibrillation treatment beyond the ICD. This has led to new studies in the field of ICD and CRT but also of catheter ablation including preventive ablation procedures in ICD patients. Further interest has also been stimulated by the use of diagnostic tools such as MRI, allowing better understanding of the underlying substrate.

The 5th EURO VT/VF symposium in Berlin, Germany, will address the entire field of VT/VF from genetics, mechanisms, diagnostics to therapeutics by bringing international physicians together.

We hope that this meeting will find your interest and we look forward to seeing you in Berlin.

K.-H. Kuck

P. Della Bella

G. Hindricks

P. Jais



8:30	Welcome and introduction KH. Kuck, Germany
	I. Session: CIEDs for the next decade: what's to come Chairs: C. Leclerque, France; W. T. Abraham, USA*
8:45	Subcutaneous ICD D. A. Theuns, Netherlands
9:05	Novel electrical device concepts for heart failure W. T. Abraham, USA*
9:25	Role of novel implantable devices for disease management programs G. Boriani, Italy
	II. Session Chairs: C. Israel, Germany
9:45	ICD implantation in patients with the potential to improve LV function. How long to wait for the ICD and how to bridge? C. Wolpert, Germany
10:05	Why should the ICD not help in patients with an EF > 35 %? W. Zareba, USA
10:25	Why does DFT testing not increase mortality when spontaneous ICD schocks do? D. Bänsch, Germany
10:45	Do patients with high DFT's die more often than patients with normal DFT's? H. Heidbuchel, Belgium

III. Session: Device-related complications: incidence, diagnosis and treatment

Chairs: C. Blomström, Sweden; M. Bongiorni, Italy

Device-related complications in the real world:

11:25 **Data from the National Danish Registry**J. Cosedis Nielson, Denmark*

1:45	Improved work flow for device implantation to reduce complications S. Richter, Germany
2:05	Device infections – Antibiotic treatment and re-implantation: How and when? C. Israel, Germany
2:25	Specaial Lecture: Lead extraction 2013 – State of the Art M. Bongiorni, Italy

12:45 – 13:45 Lunch

IV. Session: CIEDS in 2013: Current status and news from recent trials

Chairs: S. Hohnloser, Germany*; P. Brugada, Belgium*

Novel data from recent trials:

13:45	BLOCK HF
	A. Curtis, USA

14:05 **IN TIME**

G. Hindricks, Germany

14:25 **ECHO-CRT**

F. Ruschitzka, Switzerland

14:45 **SMS**

K.-H. Kuck, Germany

15:05 – 15:25 Coffee Break

V. Session: The automatic nervous system and VT/VF Chairs: H. Kottkamp, Switzerland

15:25 Special Lecture: Interaction of the ANS and VT/VF K. Shivkumar. USA

15:45 Non-Pharmacological modulation of the ANS to prevent VT/VF

P. Schwartz, Italy*

Left Cardiac Sympathetic Den

16:05 Left Cardiac Sympathetic Denervation Therapy for Malignant VF Syndromes
M. Ackermann, USA

16:25 **Device based modulation of the ANS to prevent VT/VF**P. Schauerte. Germany

16:45 Catheter ablation of sympathetic drive to prevent VT/VF V. Reddy, USA

	VI. Session
	Chairs: G. Thiene, Italy; D. Corrado, Italy
	Sports in patients with arrhythmogenic conditions:
17:05	in patients with HOCM/HCMW. Mc Kenna, United Kingdom
17:25	– in patients with ARVD H. Heidbuchel, Belgium
17:45	– in patients with ICD D. Corrado, Italy
18:05	Summary 1st day

SATURDAY

7. DECEMBER 2013

VII. Session: In Focus: Catheter ablation of VT post MI and in DCM

Chairs: P. Della Bella, Italy; P. Jais, France

8:30 The substrate of VT in DCM F. Bogun, USA

3:50 Ablation of ischemic VT: techniques and outcome W. G. Stevenson, USA

9:10 **Ablation of VT in DCM: techniques and outcome** H. Kottkamp, Switzerland

9:30 - 9:50 Coffee Break

VIII. Session: New mapping and ablation technologies for the treatment of VT/VF

Chairs: G. Hindricks, Germany; M. Hutchinson, USA

9:50 **Body surface mapping of VT/VF** P. Jais, France

10:10 Rapid Mapping with a new multipolar electrode system H. Nakagawa, USA

10:30 **Mapping of late ventricular activation** P. Della Bella, Italy

0:50	MRI-guided mapping and ablation of VT/VF C. Piorkowski, Germany
1:10	Transcutaneous ablation of VT/VF A. Al-Ahmad, USA
1:30	Pace mapping during sinus rhythm C. De Chillou, France

11:50 – 12:50 Lunch

IX. Session: In Focus: Epicardial mapping and ablation

Chairs: K.-H. Kuck, Germany; W. Stevenson, USA

- 2:50 Special Lecture: Indications for epicardial ablation: when first line, when second line and when surgical access?
 - M. Hutchinson, USA
- 13:10 Techniques for safe percutaneous epicardial access
 R. Tilz. Germany
- 13:30 Complications: recognition and treatment A. D'Avila, USA
- 13:50 Epicardial mapping and interpretation of epicardial electrograms
 K. Zeppenfeld, Netherlands
- 14:10 Surgical access to the epicardium: when and how?
 S. Benussi. Italy

X. Session: Catheter ablation of VT/VF in rare entities

Chairs: J. Atie, Brasil

- 14:30 **Congential heart disease** K. Zeppenfeld, Netherlands
- 14:50 **Acquired valvular heart disease** A. Arya, Germany
- 15:10 Catheter ablation of VT/VF in rare entities:

 Myocarditis

 C. Massahalli labby
 - G. Maccabelli, Italy
- 15:30 **Idiopathic ventricular fibrillation** P. Jais, France
- 15:50 Summary 2nd day



*requested but no commitment